ViroPharma VPHM

  1. All
  2. Commentary
  3. Stock Reports
  4. Headlines
    1. Discovery promotes VP of Finance to CFO


      Tue, 25 Mar 2014

      Bristol-Myers Squibb as well. Discovery has also appointed William Roberts as VP of Investor Relations & Corporate Communications. Roberts spent ten years with ViroPharma , which was recently acquired by Shire. ( PR ) Post your comment!

    2. Shire's 2013 In Line; Raising Our Fair Value on Higher ViroPharma Profit, Lower Cost of Capital


      Fri, 14 Feb 2014

      earlier-than-expected close to the ViroPharma acquisition. We continue to have a positive take on the ViroPharma acquisition, which strengthens the ..... incorporating more accretion from the ViroPharma acquisition into our 2014 forecast

    3. New Morningstar Analyst Report for Shire PLC

      Stock Reports

      Thu, 13 Feb 2014

      However, we have a positive view on the ViroPharma acquisition, which capitalizes on Shire ..... Shire completed the acquisition of ViroPharma in early 2014. Sales of Shire's leading ..... expected close for the acquisition of ViroPharma , excluding operating costs tied to

    4. New Morningstar Analyst Report for ViroPharma , Inc.

      Stock Reports

      Mon, 11 Nov 2013

      in midstage testing, the future of ViroPharma 's lead pipeline candidate maribavir ..... the drug failed in a Phase III trial. ViroPharma has finally secured FDA approval for ..... which should help reaccelerate growth. ViroPharma boasts the only FDA-approved product

    5. Shire's ViroPharma Acquisition Has Clear Synergies with Rare Disease Business


      Mon, 11 Nov 2013

      Shire has announced plans to acquire ViroPharma for $50 per share, or $4.2 billion ..... which amounts to a 64% premium to ViroPharma 's share price in September (prior ..... 25 per share fair value estimate for ViroPharma . However, after including $150 million

    6. Post-Vancocin, ViroPharma Remains Overvalued Due to Uncertainty Surrounding Pipeline Potential


      Thu, 1 Aug 2013

      ViroPharma 's second-quarter results continued to reflect the firm's ongoing transformation ..... with strong Cinryze sales growth offsetting Vancocin’s decline. ViroPharma maintained its full-year guidance, which is in line with our expectations

    7. ViroPharma Focuses on Pipeline as Earnings Slide in 1Q


      Wed, 1 May 2013

      ViroPharma 's VPHM first-quarter results continued to reflect the firm's ongoing transformation ..... highly profitable antibiotic company into a rare-disease operation. ViroPharma lowered its full-year product sales guidance because of the steep

    8. Generic Competition for Vancocin Causes ViroPharma's Earnings to Hit Trough in 2012


      Wed, 27 Feb 2013

      During the fourth quarter, ViroPharma VPHM reported product sales that slightly ..... competition for Vancocin, and ViroPharma 's former breadwinning antibiotic ..... valuation remains heavily tied to ViroPharma 's ability to extend Cinryze

    9. Full Impact of Generic Vancocin Evident in ViroPharma's Third Quarter


      Thu, 25 Oct 2012

      third quarter marked the first time that ViroPharma had to weather the impact of generic ..... sales drain has been swift: sales of ViroPharma 's former flagship antibiotic were ..... fourth year on the market. We think ViroPharma has done a great job of increasing disease

    10. BRIEF- ViroPharma jumps in premarket after FDA lifts hold on Cinryze testing


      Fri, 21 Sep 2012

      NEW YORK, Sept 21 (Reuters) - ViroPharma Inc : * Jumps 6.5 percent to $30 in premarket after FDA lifts hold on Cinryze testing

    « Prev12345Next »
    Content Partners